1. Home
  2. GERN vs TTMI Comparison

GERN vs TTMI Comparison

Compare GERN & TTMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • TTMI
  • Stock Information
  • Founded
  • GERN 1990
  • TTMI 1978
  • Country
  • GERN United States
  • TTMI United States
  • Employees
  • GERN N/A
  • TTMI N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • TTMI Electrical Products
  • Sector
  • GERN Health Care
  • TTMI Technology
  • Exchange
  • GERN Nasdaq
  • TTMI Nasdaq
  • Market Cap
  • GERN 2.5B
  • TTMI 2.5B
  • IPO Year
  • GERN 1996
  • TTMI 2000
  • Fundamental
  • Price
  • GERN $3.93
  • TTMI $26.24
  • Analyst Decision
  • GERN Strong Buy
  • TTMI Strong Buy
  • Analyst Count
  • GERN 10
  • TTMI 4
  • Target Price
  • GERN $7.05
  • TTMI $26.31
  • AVG Volume (30 Days)
  • GERN 6.7M
  • TTMI 533.8K
  • Earning Date
  • GERN 11-07-2024
  • TTMI 02-05-2025
  • Dividend Yield
  • GERN N/A
  • TTMI N/A
  • EPS Growth
  • GERN N/A
  • TTMI N/A
  • EPS
  • GERN N/A
  • TTMI 0.66
  • Revenue
  • GERN $29,480,000.00
  • TTMI $2,360,827,000.00
  • Revenue This Year
  • GERN $32,021.10
  • TTMI $10.68
  • Revenue Next Year
  • GERN $298.14
  • TTMI $5.34
  • P/E Ratio
  • GERN N/A
  • TTMI $39.71
  • Revenue Growth
  • GERN 9199.68
  • TTMI 3.51
  • 52 Week Low
  • GERN $1.64
  • TTMI $13.43
  • 52 Week High
  • GERN $5.34
  • TTMI $28.00
  • Technical
  • Relative Strength Index (RSI)
  • GERN 46.32
  • TTMI 70.97
  • Support Level
  • GERN $3.75
  • TTMI $25.20
  • Resistance Level
  • GERN $4.05
  • TTMI $26.82
  • Average True Range (ATR)
  • GERN 0.16
  • TTMI 0.87
  • MACD
  • GERN -0.01
  • TTMI 0.06
  • Stochastic Oscillator
  • GERN 39.13
  • TTMI 58.39

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About TTMI TTM Technologies Inc.

TTM Technologies Inc manufactures technology solutions, including mission systems, radio frequency (RF) components/RF microwave/microelectronic assemblies, quick-turn and technologically printed circuit boards (PCB). The company is based in the United States and derives roughly half of its revenue domestically. The company organizes itself into two segments: printed circuit boards and RF&S Components. The printed circuit boards segment, which contributes the majority of revenue, offers a range of printed circuit boards as well as layout design and simulation, and testing services. TTM Technologies' products are used in manufacturing, networking, telecommunications, computing, aerospace, and medical fields.

Share on Social Networks: